| Symbol | BBLGW |
|---|---|
| Name | BONE BIOLOGICS CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Industrial Specialties |
| Address | 2 BURLINGTON WOODS DRIVE,STE. 100, BURLINGTON, Massachusetts, 01803, United States |
| Telephone | +1 781 - 552-4452 |
| Fax | — |
| — | |
| Website | https://www.bonebiologics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001419554 |
| Description | Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The companys portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Additional info from NASDAQ: |
New Form DEF 14A - Bone Biologics Corp <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001493152-26-040640 <b>Size:</b> 2 MB
Read more(75% Positive) BONE BIOLOGICS CORP (BBLGW) Announces Enrollment Update for products Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations
Read moreBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Read moreNew Form DEFA14A - Bone Biologics Corp <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001493152-26-033938 <b>Size:</b> 46 KB
Read moreNew Form S-3 - Bone Biologics Corp <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001493152-26-033789 <b>Size:</b> 501 KB
Read moreBone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Read moreNew Form ARS - Bone Biologics Corp <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001493152-26-031654 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Bone Biologics Corp <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001493152-26-031653 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Bone Biologics Corp <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001493152-26-031652 <b>Size:</b> 3 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03810573 | Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis | Na | Degenerative Disc Disease | Recruiting | 2024-03-01 | 2026-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NB1 | Other | Approved | Degenerative Disc Disease | RECRUITING | NCT03810573 |
| NB1 | DEVICE | Approved | Degenerative Disc Disease | RECRUITING | NCT03810573 |